Suppr超能文献

院内获得性血小板减少症对急性心肌梗死接受直接血管成形术患者的影响。

Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.

作者信息

Nikolsky Eugenia, Sadeghi H Mehrdad, Effron Mark B, Mehran Roxana, Lansky Alexandra J, Na Yingbo, Cox David A, Garcia Eulogio, Tcheng James E, Griffin John J, Stuckey Thomas D, Turco Mark, Carroll John D, Grines Cindy L, Stone Gregg W

机构信息

Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA.

出版信息

Am J Cardiol. 2005 Aug 15;96(4):474-81. doi: 10.1016/j.amjcard.2005.04.005.

Abstract

Thrombocytopenia that develops after percutaneous coronary intervention (PCI) may result in hemorrhagic complications, requirement for blood product transfusions, and potentially thrombotic or ischemic complications. The incidence and prognostic significance of thrombocytopenia, in patients with acute myocardial infarction (AMI) who undergo primary PCI have not been evaluated. In the CADILLAC trial 2,082 patients who had AMI within 12 hours of onset without shock were prospectively randomized to receive balloon angioplasty with or without abciximab versus stenting with or without abciximab. Acquired thrombocytopenia, defined as a nadir platelet count <100 x 10(9)/L in patients who did not have baseline thrombocytopenia, developed in 50 of 1,975 qualifying patients (2.5%) after primary PCI. By multivariate analysis, acquired thrombocytopenia developed more frequently in patients who had non-insulin-requiring diabetes mellitus (odds ratio 3.88 [OR], p = 0.0002), previous statin administration (OR 3.28, p = 0.002), and use of abciximab (OR 2.06, p = 0.02) and less frequently in patients who had previous aspirin use (OR 0.26, p = 0.002), a higher baseline platelet count (OR 1.20, p < 0.0001), and greater body mass index (OR 0.90, p = 0.006). Patients who developed thrombocytopenia versus those who did not had higher in-hospital rates of major hemorrhagic complications (10.0% vs 2.7%, p = 0.01), greater requirement for blood transfusions (10.0% vs 3.9%, p = 0.05), longer hospital stay (median 4.8 vs 3.6 days, p = 0.008), and increased costs (median dollar 14,466 vs dollar 11,629, p = 0.001). All-cause mortality was markedly increased at 30 days (8.0% vs 1.6%, p = 0.0008) and at 1 year (10.0% vs 3.9%, p = 0.03) in patients who developed thrombocytopenia. In conclusion, thrombocytopenia that develops after primary PCI for AMI, although uncommon, is associated with increased hemorrhagic complications and decreased survival.

摘要

经皮冠状动脉介入治疗(PCI)后出现的血小板减少症可能导致出血并发症、需要输注血液制品,并可能引发血栓形成或缺血性并发症。急性心肌梗死(AMI)患者接受直接PCI后血小板减少症的发生率及预后意义尚未得到评估。在CADILLAC试验中,2082例发病12小时内无休克的AMI患者被前瞻性随机分组,分别接受单纯球囊血管成形术或联合阿昔单抗,以及支架植入术或联合阿昔单抗。1975例符合条件的患者中,50例(2.5%)在直接PCI后出现了获得性血小板减少症,定义为基线时无血小板减少症的患者血小板计数最低点<100×10⁹/L。多因素分析显示,获得性血小板减少症在非胰岛素依赖型糖尿病患者中更常见(比值比[OR]3.88,p = 0.0002)、既往使用他汀类药物的患者中更常见(OR 3.28,p = 0.002)、使用阿昔单抗的患者中更常见(OR 2.06,p = 0.02),而在既往使用阿司匹林的患者中较少见(OR 0.26,p = 0.002)、基线血小板计数较高的患者中较少见(OR 1.20,p < 0.0001)、体重指数较高的患者中较少见(OR 0.90,p = 0.006)。发生血小板减少症的患者与未发生者相比,住院期间主要出血并发症的发生率更高(10.0%对2.7%,p = 0.01)、输血需求更大(10.0%对3.9%,p = 0.05)、住院时间更长(中位数4.8天对3.6天,p = 0.008),且费用增加(中位数14,466美元对11,629美元,p = 0.001)。发生血小板减少症的患者30天时全因死亡率显著增加(8.0%对1.6%,p = 0.0008),1年时也显著增加(10.0%对3.9%,p = 0.03)。总之,AMI患者直接PCI后出现的血小板减少症虽然不常见,但与出血并发症增加和生存率降低相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验